NAGE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Niagen Bioscience Inc (NAGE) is not a strong buy for a beginner, long-term investor at the moment. The technical indicators are bearish, there are no significant positive catalysts, and the financial performance shows declining net income and EPS despite revenue growth. While the analyst maintains a Buy rating with a reduced price target, the lack of strong upward momentum and absence of Intellectia Proprietary Trading Signals suggest holding off on purchasing this stock for now.
The technical indicators for NAGE are bearish. The MACD histogram is negative and expanding downward, RSI is neutral at 27.802, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 4.451), with resistance levels at R1: 4.879 and R2: 5.011.
Revenue increased by 16.19% YoY in Q4 2025, and gross margin improved by 2.66% YoY to 64.14%. Analyst Susan Anderson maintains a Buy rating, citing strong demand for the core business and potential upside in the injectable business.
The MACD is bearish, and the stock has a 70% chance of declining in the next day (-0.92%) and week (-1.48%). No recent news, congress trading data, or significant insider/hedge fund activity. No Intellectia Proprietary Trading Signals are present.
In Q4 2025, revenue increased to $33,839,000 (up 16.19% YoY), but net income dropped to $4,132,000 (down 42.44% YoY). EPS declined to $0.05 (down 44.44% YoY), while gross margin improved to 64.14% (up 2.66% YoY).
Canaccord analyst Susan Anderson lowered the price target from $14 to $13 while maintaining a Buy rating, citing strong demand for the core business and potential upside in the injectable business.
